Due to the results published on the Katsanos metanalysis on paclitaxel-coated devices, the study authors of EffPac trial decided to re-check the complete cohort focusing on mortality.
These new data were published online in Radiology on 19 Jul 2020 and incorporate patients who were not included in the 2-year analysis published on 3 Mar 2020, also in Radiology.
New safety outcomes:
– All-cause mortality at 2-years: 1.2% (1/82 patients) in Luminor group and 8.2% (7/85) in POBA group.
-Risk Ratio (RR): 0.15 (95%CI: 0.02, 1.18).
Comments about Luminor DCB
With this additional review, it was clear that there is a benefit in the treatment with Luminor DCB. Actually, Prof. U. Teichgräber commented:
“The mortality risk by drug-coated balloons turned out to be even lower than shown in the original two-year results recently published at Radiology.”
“We could confirm that angioplasty with paclitaxel-coated balloons is a long-term successful and safe treatment option for intermittent claudication.”
Read more about EffPac trial outcomes.
Read the full press release at Endovascular Today.
